OIM
ECYT

Oracle Investment Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Oracle Investment Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-670,000
Closed -$16M – 32
2014
Q1 		$16M Buy
+670,000
New +$9.71M 1.82% 16

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAAMCP
Pacific Alternative Asset Management Company (PAAMCO) Irvine, California $913M AUM 18.29% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Oracle Investment Management's ECYT Position: Q2 2014 in Review

Oracle Investment Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2014, closing a stake of 670,000 shares — an estimated $16M sold.

Oracle Investment Management first reported a position in ECYT in Q1 2014 and held it in 1 quarter. The position peaked at $16M in Q1 2014. 101 funds tracked by Wall St. Rank hold ECYT as of Q2 2014.

  • Oracle Investment Management reported no remaining Endocyte, Inc. Common Stock position as of Q2 2014 after selling out during the quarter.
  • Oracle Investment Management sold 670,000 Endocyte, Inc. Common Stock shares in Q2 2014, an estimated $16M.
  • Oracle Investment Management first reported a position in Endocyte, Inc. Common Stock in Q1 2014 and held it in 1 quarter.
  • Oracle Investment Management's Endocyte, Inc. Common Stock position peaked at $16M in Q1 2014.
  • 101 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2014.

Based on Oracle Investment Management's 13F filing for Q2 2014, filed 14 Aug 2014.